Concord Biotech's Q2 FY 2025-26 Quarterly Results
- 06 Jan 2026
Result Summary
- Concord Biotech Ltd reported a 19.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 18.7%.
- Its expenses for the quarter were up by 10.3% QoQ and down 5.3% YoY.
- The net profit increased 43.1% QoQ and decreased 34.1% YoY.
- The earnings per share (EPS) of Concord Biotech Ltd stood at 6.03 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 260.41 | 217.67 | 320.21 | 19.6% | -18.7% |
Total Expenses | 177.02 | 160.43 | 186.91 | 10.3% | -5.3% |
Profit Before Tax | 83.39 | 57.24 | 133.29 | 45.7% | -37.4% |
Tax | 22.62 | 14.67 | 34.59 | 54.2% | -34.6% |
Profit After Tax | 63.06 | 44.06 | 95.74 | 43.1% | -34.1% |
Earnings Per Share | 6.03 | 4.21 | 9.15 | 43.2% | -34.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Concord Biotech Ltd is a company that operates within the biotechnology industry. It is primarily engaged in the production and distribution of biopharmaceutical products. The company's product portfolio includes active pharmaceutical ingredients (APIs) and finished formulations that cater to various therapeutic areas. Concord Biotech has a reputation for innovation in biotechnological applications and consistently focuses on expanding its research and development capabilities. While recent major developments or strategic shifts within the company are not explicitly available, Concord Biotech remains a key player in the biotech sector, providing essential pharmaceuticals to a broad market.
Revenue
In the second quarter of the fiscal year 2026 (Q2FY26), Concord Biotech Ltd reported a total income of ₹260.41 crores. This represents a quarter-over-quarter (QoQ) increase of 19.6% from ₹217.67 crores in Q1FY26. However, when compared to the same quarter in the previous year (Q2FY25), there is an 18.7% decrease from ₹320.21 crores, indicating a shift in revenue performance year-over-year (YoY). The revenue changes reflect the company's operational dynamics over the quarters, with significant variations compared to the previous fiscal year.
Profitability
Concord Biotech Ltd's profitability metrics for Q2FY26 show a profit before tax of ₹83.39 crores, marking a substantial QoQ increase of 45.7% from ₹57.24 crores in Q1FY26. Despite this quarterly growth, there is a YoY decline of 37.4% from ₹133.29 crores in Q2FY25. The tax expenses for Q2FY26 were ₹22.62 crores, which increased by 54.2% QoQ from ₹14.67 crores in the previous quarter, yet decreased by 34.6% YoY. The profit after tax stood at ₹63.06 crores, reflecting a 43.1% rise QoQ but a 34.1% drop YoY. Earnings per share for the quarter were ₹6.03, up by 43.2% QoQ, but down by 34.1% compared to the previous year.
Operating Metrics
The total expenses for Concord Biotech in Q2FY26 were ₹177.02 crores, which represents a 10.3% increase QoQ from ₹160.43 crores in Q1FY26. When compared YoY, expenses decreased by 5.3% from ₹186.91 crores in Q2FY25. This fluctuation highlights operational cost management and its impact on the company's financials. The profitability metrics indicate both efficiency and cost dynamics that have influenced the company's financial performance. The data suggests a varied financial landscape influenced by both internal and external factors impacting Concord Biotech's operational metrics.